Patterson-UTI Energy, Inc. (PTEN) is set to report fourth-quarter earnings on Feb. 5. The Zacks Consensus Estimate for earnings is pegged at a loss of 10 cents per share and the same for revenues is pinned at $1.21 billion.Let us delve into the factors that are likely to have influenced PTEN’s performance in the to-be-reported quarter. Before that, it is worth taking a look at the company’s performance in the last reported quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Highl ...

BERWYN, Pa., Feb. 4, 2025 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced its financial results for the fourth quarter ended December 31, 2024. AMETEK's fourth quarter 2024 sales were a record $1.76 billion, a 2% increase over the fourth quarter of 2023. Operating income increased 5% to a record $469.0 million and operating margins were 26.6% in the quarter, up 90 basis points from the prior year. Operating cash flow in the quarter was a record $550.0 million, free cash flow was a record $498.3 mil ...

BERWYN, Pa., Feb. 4, 2025 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced the acquisition of Kern Microtechnik, a leading manufacturer of high-precision machining and optical inspection solutions.Kern specializes in the design and manufacture of ultra-precision manufacturing solutions capable of achieving sub-micron level accuracy. Kern's advanced product portfolio includes high-precision machining solutions and optical tool inspection systems. Their highly engineered solutions support a wide range ...

The Ferrari F50 at Salon Prive London, held at the Royal Chelsea Hospital.Luxury carmaker Ferrari on Tuesday reported a significant upswing in full-year net profit, citing a strong product mix and growing demand for personalization.Ferrari posted net profit of 1.53 billion euros ($1.58 billion) for the full-year 2024 period, reflecting a 21% increase from the previous year.Milan-listed shares of the company rose 4.8% on the news before trading was halted.This is breaking news. Please refresh for updates. ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Centene reported $3.3 billion in 2024 profits as Obamacare enrollment and premium revenue helped ... [+] overcome a big dip in Medicaid enrollment. In this photo, the building housing Centene Corporation headquarters is seen Thursday, July 2, 2015, in Clayton, Mo. (AP Photo/Jeff Roberson)ASSOCIATED PRESSCentene Tuesday reported $3.3 billion in 2024 profits as Obamacare enrollment and premium revenue helped overcome a big dip in Medicaid enrollment.Centene, which sells an array of government subsidized healt ...

Grew Net sales for the quarter by 2.1% and organic Net sales by 3.8% with organic growth in both Battery and Auto Care.1 Gross margin for the first quarter was 36.8% and 40.0% as adjusted, a 50 bps improvement over prior year Adjusted Gross margin.1 Delivered Earnings per share of $0.30 and Adjusted Earnings per share of $0.67, an increase of 14% on an adjusted basis.1 Reduced net leverage to 4.7 times driven by debt pay down and Adjusted EBITDA growth.1 Increases organic Net sales fiscal year outlook to 2 ...

Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM ESTCARMIEL, Israel, Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at ...

Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel, Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at ...

My previous investment thought on Dynatrace (NYSE: DT ) (published on 15th November) was a buy rating because I was bullish on the underlying demand momentum and was positive that sales productivity will improve as salesI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. ...